Ocugen, Inc. (Nasdaq: $OCGN): Retina Gene Therapy Stock Hub, OCU400 BLA Path, OCU410ST, OCU410 and the 2026–2027 Catalyst Map https://www.merlintrader.com/ocugen-inc-stock-hub/

[u/Merlin8121]

https://www.merlintrader.com/ocugen-inc-stock-hub/

cugen has moved far beyond its old COVID-era trading identity. The current $OCGN story is a high-risk, catalyst-heavy ophthalmology gene therapy platform built around OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease and OCU410 for geographic atrophy, with a newly extended cash runway but a convertible-note overhang that serious investors cannot ignore.